MeSH tree: D23.101.140
Most cancer deaths are due to the metastatic spread and growth of tumor cells at distant sites. Identifying appropriate treatments for patients with metastatic disease is challenging because of limited biomarkers and detection ...
Aug 15, 2023
0
44
Recent research from the Tanz Center for Research in Neurodegenerative Diseases in the University of Toronto's Temerty Faculty of Medicine is challenging long-held views of how a hormone called somatostatin influences the ...
Jul 5, 2023
0
83
By monitoring early-response biomarkers in men undergoing 177Lu-PSMA prostate cancer treatment, physicians can personalize dosing intervals, significantly improving patient outcomes.
Jun 27, 2023
0
48
Tiny packets of molecular cargo shed by cancer cells seed the foundations for metastasis at distant sites in the body.
Jun 19, 2023
0
61
For patients with adenomyosis, mifepristone is efficacious and has acceptable tolerability, according to a study published online June 12 in JAMA Network Open.
Jun 14, 2023
0
49
The most common screening test for prostate cancer so often returns a false positive result that it's no longer recommended for men older than 70, and it's offered as a personal choice for younger men.
Jun 10, 2023
0
100
Researchers at the Department of Obstetrics and Gynecology, Peking University Third Hospital in Beijing, China, have developed a new ovarian cancer screening technique. In a paper, "Profiling the metabolome of uterine fluid ...
Finding cancer quickly is key in securing the best possible outcome for the patient.
Jun 5, 2023
0
39
Finding cancer quickly is key in securing the best possible outcome for the patient.
Jun 5, 2023
0
35
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators ...
Apr 6, 2023
0
66
